Revue du Rhumatisme (Edition Francaise)最新文献

{"title":"Arthropathie destructrice de l’épaule secondaire à une syringomyélie","authors":"Daniel Wendling","doi":"10.1016/j.rhum.2025.05.006","DOIUrl":"10.1016/j.rhum.2025.05.006","url":null,"abstract":"","PeriodicalId":38943,"journal":{"name":"Revue du Rhumatisme (Edition Francaise)","volume":"93 3","pages":"Pages 401-402"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147961128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ostéopathie au méthotrexate","authors":"Daniel Wendling, Mickael Chouk, Olivier Fakih, Frank Verhoeven, Clément Prati","doi":"10.1016/j.rhum.2025.04.007","DOIUrl":"10.1016/j.rhum.2025.04.007","url":null,"abstract":"","PeriodicalId":38943,"journal":{"name":"Revue du Rhumatisme (Edition Francaise)","volume":"93 3","pages":"Pages 397-398"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147961185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Manifestations rhumatologiques des syndromes myélodysplasiques","authors":"Arsène Mekinian,&nbsp;Olivier Fain","doi":"10.1016/j.rhum.2025.09.021","DOIUrl":"10.1016/j.rhum.2025.09.021","url":null,"abstract":"<div><div>Les syndromes myélodysplasiques (SMD) peuvent être associés à des manifestations extra-hématologiques inflammatoires ou auto-immunes dans 10 à 30 % des cas. Ces atteintes comprennent des tableaux articulaires, cutanés, systémiques ou inclassables. Les formes articulaires incluent des polyarthrites non érosives, des tableaux de PPR, de RS3PE ou des atteintes axiales liées au syndrome VEXAS. Les manifestations cutanées fréquentes regroupent les dermatoses neutrophiliques et les vascularites. Certaines formes miment des connectivites ou des vascularites systémiques comme la maladie de Behçet ou l’artérite giganto-cellulaire, parfois associées à des anomalies cytogénétiques comme la trisomie 8. La physiopathologie implique des mutations somatiques clonales (TET2, IDH1/2, KRAS, <em>UBA1</em>). Le traitement repose sur une approche ciblant soit l’inflammation (biothérapies) soit le clone myéloïde (hypométhylants), selon la sévérité clinique, le profil mutationnel et l’évolution hématologique.</div></div><div><div>Myelodysplastic syndromes (MDS) can be associated with inflammatory or autoimmune extra-hematologic manifestations in 10 to 30 % of cases. These include articular, cutaneous, systemic, or unclassifiable presentations. Joint involvement encompasses non-erosive polyarthritis, PMR-like symptoms, RS3PE, or axial disease often linked to VEXAS syndrome. Cutaneous manifestations are frequent, including neutrophilic dermatoses and leukocytoclastic vasculitis. Some forms mimic systemic vasculitis or connective tissue diseases such as Behçet or giant-cell arteritis, sometimes associated with cytogenetic anomalies like trisomy 8. The pathophysiology involves clonal somatic mutations (TET2, IDH1/2, KRAS, <em>UBA1</em>). Treatment strategies rely on either anti-inflammatory approaches (biologics) or targeting the myeloid clone (hypomethylating agents), depending on clinical severity, mutational profile, and hematologic evolution.</div></div>","PeriodicalId":38943,"journal":{"name":"Revue du Rhumatisme (Edition Francaise)","volume":"93 3","pages":"Pages 439-442"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147961192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mastocytose et ostéoporose","authors":"Yannick Degboé","doi":"10.1016/j.rhum.2025.01.023","DOIUrl":"10.1016/j.rhum.2025.01.023","url":null,"abstract":"<div><div>La mastocytose est un groupe hétérogène de maladies rares caractérisées par une dérégulation du compartiment mastocytaire et avec pour tissu cible majeur : l’os. L’infiltration du tissu osseux et la libération de médiateurs par ces mastocytes anormaux sont responsables du développement d’une ostéoporose, de douleurs osseuses et d’anomalies de la structure osseuse. Dans cette revue, nous examinerons les caractéristiques de l’ostéoporose associée à la mastocytose, nous analyserons les données disponibles dans la littérature concernant sa prise en charge et nous proposerons une stratégie thérapeutique. Cette stratégie s’appuie à la fois sur les connaissances scientifiques actuelles et sur l’expérience acquise au sein de notre centre de référence pour la mastocytose (CEREMAST de Toulouse).</div></div><div><div>Mastocytosis is a heterogeneous group of rare diseases characterized by dysregulation of the mast cell compartment, with a major target tissue being the bone. The infiltration of bone tissue and the release of mediators by these abnormal mast cells are responsible for the development of osteoporosis, bone pain, and structural abnormalities of the bone. In this review, we will examine the characteristics of osteoporosis associated with mastocytosis, analyse the available literature data on its management, and propose a therapeutic strategy. This strategy is based on both current scientific knowledge and the experience gained from our reference centre for mastocytosis (CEREMAST in Toulouse).</div></div>","PeriodicalId":38943,"journal":{"name":"Revue du Rhumatisme (Edition Francaise)","volume":"93 3","pages":"Pages 365-372"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147961131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rhumatologie et oncologie : interactions cliniques et thérapeutiques","authors":"Béatrice Bouvard","doi":"10.1016/j.rhum.2026.04.001","DOIUrl":"10.1016/j.rhum.2026.04.001","url":null,"abstract":"","PeriodicalId":38943,"journal":{"name":"Revue du Rhumatisme (Edition Francaise)","volume":"93 3","pages":"Pages 404-405"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147961129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Manifestations rhumatologiques des traitements du cancer et leur prise en charge","authors":"Alice Tison ,&nbsp;Samuel Bitoun ,&nbsp;Thomas Escoda ,&nbsp;Laurent Chiche","doi":"10.1016/j.rhum.2025.12.021","DOIUrl":"10.1016/j.rhum.2025.12.021","url":null,"abstract":"&lt;div&gt;&lt;div&gt;Avec les progrès grandissants et la complexification de l’arsenal thérapeutique en oncologie, une actualisation concernant les toxicités rhumatologiques de ces traitements est indispensable. Les arthromyalgies associées à certaines chimiothérapies et à l’hormonothérapie anticancéreuse sont bien connues. Des vascularites peuvent rarement survenir avec les thérapies ciblées, notamment avec les anti-VEGF. L’utilisation de cellules T à récepteur antigénique chimérique (&lt;em&gt;CAR-T cells&lt;/em&gt;) qui a bouleversé l’onco-hématologie est pourvoyeuse de syndromes de relargage cytokiniques, avec des prises en charges codifiées, mais peut également être rarement responsable de toxicités rhumatologiques immuno-médiées. L’avènement des inhibiteurs de point de contrôle immunitaire (ICI) et leurs indications croissantes représente un tournant majeur, avec l’apparition de nouvelles entités nosologiques, celles des effets secondaires immuno-médiés (irAEs). Environ 5 % des patients peuvent présenter une arthrite inflammatoire, avec une atteinte principalement oligo- ou polyarticulaire, ou encore pseudo-polyarthrite rhizomélique-like ou PPR-like. Les fasciites et myosites sont plus rares mais peuvent être graves. Des poussées d’un rhumatisme inflammatoire préexistant (rhumatisme psoriasique) peuvent aussi survenir dans 30 à 50 % des cas. Alors que la corticothérapie est utilisée en première ligne, à la posologie minimale efficace et pour une durée la plus courte possible, la sécurité d’emploi des &lt;em&gt;disease modifying antirheumatic drugs&lt;/em&gt; (DMARDs) conventionnels, biologiques et ciblés en association avec un ICI vis-à-vis de la réponse anti-tumorale reste à déterminer.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div&gt;With the ongoing advancements and increasing complexity of the therapeutic arsenal in oncology, an updated overview of the rheumatologic toxicities associated with these treatments is warranted. While aspecific arthralgia and myalgia related to chemotherapies and anti-cancer hormone therapies are well recognized, vasculitides may rarely occur with targeted therapies, such as anti-VEGF agents. The use of chimeric antigen receptor T cells (CAR-T cells) has transformed the field of onco-hematology. While they are associated with cytokine release syndrome — whose management is well standardized — they may also rarely induce immune-mediated rheumatologic toxicities. The emergence of immune checkpoint inhibitors (ICIs) and their expanding indications represent a major turning point, marked by the occurrence of new nosological entities: the immune-related adverse events (irAEs). Approximately 5% of patients develop inflammatory arthritis, most often presenting as oligo- or poly-arthritis, or as polymyalgia rheumatica–like syndromes. Fasciitis and myositis are less common but may be severe. Flares of preexisting inflammatory rheumatic diseases (psoriatic arthritis) can also occur in 30–50% of cases. While glucocorticoids are used as first-line therapy — at the lowest effective d","PeriodicalId":38943,"journal":{"name":"Revue du Rhumatisme (Edition Francaise)","volume":"93 3","pages":"Pages 406-416"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147961189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progression de fractures vertébrales multiples après arrêt du dénosumab et sous romosozumab","authors":"Michail Krikelis ,&nbsp;Susana Gazi ,&nbsp;Georgios Trovas ,&nbsp;Konstantinos Makris ,&nbsp;Efstathios Chronopoulos ,&nbsp;Symeon Tournis","doi":"10.1016/j.rhum.2025.09.004","DOIUrl":"10.1016/j.rhum.2025.09.004","url":null,"abstract":"<div><h3>Introduction</h3><div>Le dénosumab est largement utilisé dans le traitement de l’ostéoporose post-ménopausique et son arrêt s’accompagne parfois de fractures vertébrales multiples. La capacité du romosozumab à prévenir cet effet rebond n’a pas été rapportée.</div></div><div><h3>Présentation du cas</h3><div>Nous décrivons le cas d’une patiente de 68 ans atteinte d’ostéoporose ménopausique sous romosozumab et présentant des fractures vertébrales multiples consécutives à l’arrêt du dénosumab. L’ajout de romosozumab n’a pas empêché la survenue de nouvelles fractures vertébrales associées à cet effet rebond. La patiente a arrêté le romosozumab et repris le dénosumab. Après six mois, aucune nouvelle fracture vertébrale n’était apparue, la densité minérale osseuse avait augmenté et les taux de marqueurs du remodelage osseux restaient faibles.</div></div><div><h3>Discussion</h3><div>Ce cas clinique rapporte l’efficacité du romosozumab dans la prévention de la cascade de fractures vertébrales multiples attribuables à l’arrêt du dénosumab. Il semble que le traitement par romosozumab pourrait ne pas suffire à éviter ce phénomène. Le dénosumab, voire une combinaison de dénosumab et de romosozumab, pourrait constituer une autre option.</div></div><div><h3>Introduction</h3><div>Denosumab (Dmab) is widely used for the treatment of post-menopausal osteoporosis. Its discontinuation is sometimes accompanied by multiple vertebral fractures. Romosozumab (Rmab) has not been tested for its ability to prevent the rebound phenomenon.</div></div><div><h3>Case presentation</h3><div>We present the case of a 68-year-old female patient with post-menopausal osteoporosis under treatment with Rmab who presented with multiple vertebral fractures after denosumab discontinuation. The addition of Rmab did not prevent new-onset rebound-associated vertebral fractures. The patient discontinued Rmab and Dmab was re-initiated. After six months, no new vertebral fractures occurred, bone mineral density increased and bone turnover markers remained suppressed.</div></div><div><h3>Discussion</h3><div>Our clinical case illustrates the effectiveness of Rmab to prevent the multiple vertebral fracture cascade attributable to discontinuation of Dmab. We believe that treatment with Rmab might not be enough to prevent this phenomenon. Treatment with Dmab or possibly combination treatment with Dmab and Rmab could be another treatment option.</div></div>","PeriodicalId":38943,"journal":{"name":"Revue du Rhumatisme (Edition Francaise)","volume":"93 3","pages":"Pages 390-394"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147961183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sarcoïdose osseuse : lésions extensives des mains","authors":"Lilia Nacef ,&nbsp;Johanna Sigaux ,&nbsp;Elodie Rivière ,&nbsp;Luca Semerano ,&nbsp;Hilario Nunes ,&nbsp;Nathalie Saidenberg-Kermanac’h","doi":"10.1016/j.rhum.2025.05.005","DOIUrl":"10.1016/j.rhum.2025.05.005","url":null,"abstract":"","PeriodicalId":38943,"journal":{"name":"Revue du Rhumatisme (Edition Francaise)","volume":"93 3","pages":"Pages 399-400"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147961186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Manifestations rhumatologiques paranéoplasiques","authors":"Edouard Pertuiset,&nbsp;Omar Al Tabaa","doi":"10.1016/j.rhum.2025.09.009","DOIUrl":"10.1016/j.rhum.2025.09.009","url":null,"abstract":"<div><div>Les syndromes paranéoplasiques en rhumatologie regroupent divers syndromes dont l’origine paranéoplasique est rarement certaine. Il est rare que le mécanisme en soit connu comme c’est le cas pour l’ostéomalacie hypophosphatémique oncogénique qui est le plus souvent liée à une tumeur bénigne d’origine mésenchymateuse sécrétant du FGF-23. Le caractère paranéoplasique est parfois certain mais le mécanisme est inconnu : ostéoarthropathie hypertrophiante, syndrome de Weber Christian, réticulohistiocytose multicentrique, syndrome fasciite palmaire et polyarthrite, dermatomyosite avec anti-TIF-1γ. Dans d’autres cas, le caractère paranéoplasique est incertain même si une association statistique avec un cancer est démontrée : sclérodermie systémique avec anti-RNAP III. Dans tous ces cas, la recherche exhaustive d’une tumeur s’impose. Une origine paranéoplasique est soupçonnée dans certains cas de vascularite systémique, de syndrome RS3PE ou de polyarthrite séronégative. La relation temporelle est fondamentale pour affirmer la nature paranéoplasique d’un syndrome.</div></div><div><div>Paraneoplastic syndromes in rheumatology include various syndromes whose paraneoplastic origin is rarely certain. It is rare that the mechanism is known, as it is the case for oncogenic hypophosphatemic osteomalacia, which is most often linked to a benign tumor of mesenchymal origin secreting FGF-23. The paraneoplastic nature is sometimes certain, but the mechanisms are unknown: hypertrophic osteoarthropathy, Weber Christian syndrome, multicentric reticulohistiocytosis, palmar fasciitis and polyarthritis syndrome, dermatomyositis with anti-TIF-1γ. In other cases, the paraneoplastic nature is uncertain even if a statistical association with cancer is demonstrated: systemic sclerosis with anti-RNAP III. In all these cases, a comprehensive search for a tumor is required. A paraneoplastic origin is suspected in some cases of systemic vasculitis, RS3PE syndrome or seronegative polyarthritis. The temporal relationship is fundamental to affirm the paraneoplastic nature of a syndrome.</div></div>","PeriodicalId":38943,"journal":{"name":"Revue du Rhumatisme (Edition Francaise)","volume":"93 3","pages":"Pages 443-448"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147960858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ce mois-ci dans Joint Bone Spine 2026 (Mai);93/3","authors":"Marie-Christophe Boissier","doi":"10.1016/j.rhum.2026.03.001","DOIUrl":"10.1016/j.rhum.2026.03.001","url":null,"abstract":"","PeriodicalId":38943,"journal":{"name":"Revue du Rhumatisme (Edition Francaise)","volume":"93 3","pages":"Pages 307-309"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147960862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}